Modulation of Tumor-Associated Macrophages (TAM) Phenotype by Platelet-Activating Factor (PAF) Receptor

Platelet-activating factor (PAF) plays an important role in the pathogenesis of several types of tumors. The biological effects of PAF are mediated by the PAF receptor (PAFR), which can be expressed by tumor cells and host cells that infiltrate the tumor microenvironment. In the present study, we investigated the role of PAFR expressed by leukocytes that infiltrate two types of tumors, one that expresses PAFR (TC-1 carcinoma) and another that does not express the receptor (B16F10 melanoma) implanted in mice that express the receptor or not (PAFR KO). It was found that both tumors grew significantly less in PAFR KO than in wild-type (WT) mice. Analysis of the leukocyte infiltration shown in PAFR KO increased the frequency of neutrophils (Gr1+) and of CD8+ lymphocytes in B16F10 tumors and of CD4+ lymphocytes in TC-1 tumors. PAFR KO also had a higher frequency of M1-like (CD11c+) and lower M2-like (CD206+) macrophages infiltrated in both tumors. This was confirmed in macrophages isolated from the tumors that showed higher iNOS, lower arginase activity, and lower IL10 expression in PAFR KO tumors than WT mice. These data suggest that in the tumor microenvironment, endogenous PAF-like activity molecules bind PAFR in macrophages which acquire an M2-like profile and this promotes tumor growth

Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease:results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study

BACKGROUND: Anti-drug antibodies are associated with treatment failure to anti-TNF agents in patients with inflammatory bowel disease (IBD).AIM: To assess whether immunogenicity to a patient's first anti-TNF agent would be associated with immunogenicity to the second, irrespective of drug sequence METHODS: We conducted a UK-wide, multicentre, retrospective cohort study to report rates of immunogenicity and treatment failure of second anti-TNF therapies in 1058 patients with IBD who underwent therapeutic drug monitoring for both infliximab and adalimumab. The primary outcome was immunogenicity to the second anti-TNF agent, defined at any timepoint as an anti-TNF antibody concentration ≥9 AU/ml for infliximab and ≥6 AU/ml for adalimumab.RESULTS: In patients treated with infliximab and then adalimumab, those who developed antibodies to infliximab were more likely to develop antibodies to adalimumab, than patients who did not develop antibodies to infliximab (OR 1.99, 95%CI 1.27-3.20, p = 0.002). Similarly, in patients treated with adalimumab and then infliximab, immunogenicity to adalimumab was associated with subsequent immunogenicity to infliximab (OR 2.63, 95%CI 1.46-4.80, p < 0.001). For each 10-fold increase in anti-infliximab and anti-adalimumab antibody concentration, the odds of subsequently developing antibodies to adalimumab and infliximab increased by 1.73 (95% CI 1.38-2.17, p < 0.001) and 1.99 (95%CI 1.34-2.99, p < 0.001), respectively. Patients who developed immunogenicity with undetectable drug levels to infliximab were more likely to develop immunogenicity with undetectable drug levels to adalimumab (OR 2.37, 95% CI 1.39-4.19, p < 0.001). Commencing an immunomodulator at the time of switching to the second anti-TNF was associated with improved drug persistence in patients with immunogenic, but not pharmacodynamic failure.CONCLUSION: Irrespective of drug sequence, immunogenicity to the first anti-TNF agent was associated with immunogenicity to the second, which was mitigated by the introduction of an immunomodulator in patients with immunogenic, but not pharmacodynamic treatment failure

Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF Therapy (IMSAT) therapeutic drug monitoring study

BACKGROUND: Anti-drug antibodies are associated with treatment failure to anti-TNF agents in patients with inflammatory bowel disease (IBD).AIM: To assess whether immunogenicity to a patient's first anti-TNF agent would be associated with immunogenicity to the second, irrespective of drug sequence METHODS: We conducted a UK-wide, multicentre, retrospective cohort study to report rates of immunogenicity and treatment failure of second anti-TNF therapies in 1058 patients with IBD who underwent therapeutic drug monitoring for both infliximab and adalimumab. The primary outcome was immunogenicity to the second anti-TNF agent, defined at any timepoint as an anti-TNF antibody concentration ≥9 AU/ml for infliximab and ≥6 AU/ml for adalimumab.RESULTS: In patients treated with infliximab and then adalimumab, those who developed antibodies to infliximab were more likely to develop antibodies to adalimumab, than patients who did not develop antibodies to infliximab (OR 1.99, 95%CI 1.27-3.20, p = 0.002). Similarly, in patients treated with adalimumab and then infliximab, immunogenicity to adalimumab was associated with subsequent immunogenicity to infliximab (OR 2.63, 95%CI 1.46-4.80, p < 0.001). For each 10-fold increase in anti-infliximab and anti-adalimumab antibody concentration, the odds of subsequently developing antibodies to adalimumab and infliximab increased by 1.73 (95% CI 1.38-2.17, p < 0.001) and 1.99 (95%CI 1.34-2.99, p < 0.001), respectively. Patients who developed immunogenicity with undetectable drug levels to infliximab were more likely to develop immunogenicity with undetectable drug levels to adalimumab (OR 2.37, 95% CI 1.39-4.19, p < 0.001). Commencing an immunomodulator at the time of switching to the second anti-TNF was associated with improved drug persistence in patients with immunogenic, but not pharmacodynamic failure.CONCLUSION: Irrespective of drug sequence, immunogenicity to the first anti-TNF agent was associated with immunogenicity to the second, which was mitigated by the introduction of an immunomodulator in patients with immunogenic, but not pharmacodynamic treatment failure

Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease:results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study

BACKGROUND: Anti-drug antibodies are associated with treatment failure to anti-TNF agents in patients with inflammatory bowel disease (IBD).AIM: To assess whether immunogenicity to a patient's first anti-TNF agent would be associated with immunogenicity to the second, irrespective of drug sequence METHODS: We conducted a UK-wide, multicentre, retrospective cohort study to report rates of immunogenicity and treatment failure of second anti-TNF therapies in 1058 patients with IBD who underwent therapeutic drug monitoring for both infliximab and adalimumab. The primary outcome was immunogenicity to the second anti-TNF agent, defined at any timepoint as an anti-TNF antibody concentration ≥9 AU/ml for infliximab and ≥6 AU/ml for adalimumab.RESULTS: In patients treated with infliximab and then adalimumab, those who developed antibodies to infliximab were more likely to develop antibodies to adalimumab, than patients who did not develop antibodies to infliximab (OR 1.99, 95%CI 1.27-3.20, p = 0.002). Similarly, in patients treated with adalimumab and then infliximab, immunogenicity to adalimumab was associated with subsequent immunogenicity to infliximab (OR 2.63, 95%CI 1.46-4.80, p < 0.001). For each 10-fold increase in anti-infliximab and anti-adalimumab antibody concentration, the odds of subsequently developing antibodies to adalimumab and infliximab increased by 1.73 (95% CI 1.38-2.17, p < 0.001) and 1.99 (95%CI 1.34-2.99, p < 0.001), respectively. Patients who developed immunogenicity with undetectable drug levels to infliximab were more likely to develop immunogenicity with undetectable drug levels to adalimumab (OR 2.37, 95% CI 1.39-4.19, p < 0.001). Commencing an immunomodulator at the time of switching to the second anti-TNF was associated with improved drug persistence in patients with immunogenic, but not pharmacodynamic failure.CONCLUSION: Irrespective of drug sequence, immunogenicity to the first anti-TNF agent was associated with immunogenicity to the second, which was mitigated by the introduction of an immunomodulator in patients with immunogenic, but not pharmacodynamic treatment failure

The role of HPV-associated tumor metabolism on human macrophage phenotype.

O lactato, produto do metabolismo alterado das células tumorais, possui papel na modulação de fenótipo supressor em células imunes. Macrófagos são uma das principais células do microambiente tumoral, sendo pró-tumorais em câncer cervical. O objetivo desse trabalho foi avaliar o efeito do lactato no fenótipo de macrófagos associados a células tumorais derivadas de câncer cervical. Linhagens celulares positivas e negativa para HPV foram utilizadas para formação de esferoides tumorais, os quais receberam monócitos de doadores saudáveis para diferenciação em macrófagos. Macrófagos cultivados com linhagens tumorais positivas para HPV apresentaram fenótipo misto e pró-tumoral, enquanto os cultivados com a linhagem negativa, um fenótipo mais anti-tumoral. A inibição da enzima lactato desidrogenase, nas células tumorais, promoveu diferentes efeitos no fenótipo dos macrófagos, dependendo do tipo celular a que estavam associados. Essas alterações diminuíram o aspecto pró-tumoral desses macrófagos, que induziram maior proliferação de linfócitos T e morte de células tumorais.The lactate, product of the altered metabolism of tumor cells, is associated with the induction of a suppressor phenotype in immune cells. Macrophages are one of the major cells of the tumor microenvironment, and are pro-tumor in cervical cancer. The aim of this study was to evaluate the effect of lactate in the phenotype of macrophages associated with tumor cells derived from cervical cancer. HPV positive and negative cell lines were used for formation of tumor spheroids, which received healthy donor monocytes to differentiate into macrophages. Macrophages cultivated with HPV positive tumor cell lines presented a mixed and pro-tumor phenotype, while macrophages cultivated with the HPV negative cell line, a more anti-tumor phenotype. Inhibition of lactate dehydrogenase in the tumor cells promoted different effects on macrophages phenotype, depending on the cell type that they were associated. These changes decreased the pro-tumor property of macrophages, which were able to induced T cell proliferation and tumor cell death

Immunomodulation by human papillomavirus associated tumors.

O câncer cervical é o segundo mais comum em mulheres em países em desenvolvimento, sendo causado por infecção persistente por Papilomavírus Humano (HPV). Quando esta persistência ocorre, entre outros fatores, está relacionada a mecanismos de evasão do sistema imune apresentados pelo vírus. A frequência de macrófagos aumenta com a progressão da lesão cervical e há aumento de células mielóides no baço de camundongos com tumor. Este trabalho tem como objetivo observar os efeitos sistêmicos de tumores associados ao HPV sobre a proliferação e recrutamento de células do sistema imune e identificar fatores que tenham papel nesses mecanismos. Utilizando modelos de tumor in vivo, observou-se que tumores associados ao HPV recrutam mais células para o tumor e induzem maior proliferação celular. Também avaliamos o perfil de expressão de citocinas nas linhagens tumorais e o perfil geral de expressão de proteínas através de eletroforese 2D. Com isto, demonstramos que linhagens tumorais positivas para HPV apresentam maior expressão de IL-6, IL-8, CXCL1, sICAM e Serpina E1.Cervical cancer is the second most common type of cancer in women in developing countries. Its main etiologic factor is persistent infection with high risk human papillomavirus (HPV). This persistence occurs only in some cases and, among other factors, is related to mechanisms of immune evasion displayed by the virus. There is an increase in the frequency of macrophages proportional to cervical intraepithelial lesion grade and an increase of myeloid cells in the spleen of tumor bearing mice. This work aims to observe the systemic effects of HPV associated tumors on the proliferation and recruitment of immune cells, and identify factors that have a role in these mechanisms. Using in vivo tumor models, we found that HPV positive tumors recruit a higher percentage of cells and induce cellular proliferation. We also studied cytokine expression profiles of tumor cell lines, and performed proteomic assay with tumor cells transduced with HPV oncogenes. Our data shows that HPV associated tumor cell lines display higher expression of IL-6, IL-8, CXCL1, sICAM and Serpin E1

Immunomodulation by human papillomavirus associated tumors.

O câncer cervical é o segundo mais comum em mulheres em países em desenvolvimento, sendo causado por infecção persistente por Papilomavírus Humano (HPV). Quando esta persistência ocorre, entre outros fatores, está relacionada a mecanismos de evasão do sistema imune apresentados pelo vírus. A frequência de macrófagos aumenta com a progressão da lesão cervical e há aumento de células mielóides no baço de camundongos com tumor. Este trabalho tem como objetivo observar os efeitos sistêmicos de tumores associados ao HPV sobre a proliferação e recrutamento de células do sistema imune e identificar fatores que tenham papel nesses mecanismos. Utilizando modelos de tumor in vivo, observou-se que tumores associados ao HPV recrutam mais células para o tumor e induzem maior proliferação celular. Também avaliamos o perfil de expressão de citocinas nas linhagens tumorais e o perfil geral de expressão de proteínas através de eletroforese 2D. Com isto, demonstramos que linhagens tumorais positivas para HPV apresentam maior expressão de IL-6, IL-8, CXCL1, sICAM e Serpina E1.Cervical cancer is the second most common type of cancer in women in developing countries. Its main etiologic factor is persistent infection with high risk human papillomavirus (HPV). This persistence occurs only in some cases and, among other factors, is related to mechanisms of immune evasion displayed by the virus. There is an increase in the frequency of macrophages proportional to cervical intraepithelial lesion grade and an increase of myeloid cells in the spleen of tumor bearing mice. This work aims to observe the systemic effects of HPV associated tumors on the proliferation and recruitment of immune cells, and identify factors that have a role in these mechanisms. Using in vivo tumor models, we found that HPV positive tumors recruit a higher percentage of cells and induce cellular proliferation. We also studied cytokine expression profiles of tumor cell lines, and performed proteomic assay with tumor cells transduced with HPV oncogenes. Our data shows that HPV associated tumor cell lines display higher expression of IL-6, IL-8, CXCL1, sICAM and Serpin E1